Scinai Immunotherapeutics Stock Set to Reverse Split on Friday, August 21st (NASDAQ:SCNI)

Shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) are scheduled to reverse split on the morning of Friday, August 21st. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, August 20th.

Scinai Immunotherapeutics Price Performance

SCNI opened at $0.24 on Monday. The firm has a market capitalization of $1.25 million, a PE ratio of -0.23 and a beta of 2.08. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.35 and a quick ratio of 1.35. The business’s 50-day moving average is $0.27 and its two-hundred day moving average is $0.53. Scinai Immunotherapeutics has a 1 year low of $0.21 and a 1 year high of $1.79.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On Scinai Immunotherapeutics

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC grew its holdings in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the quarter. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. 58.41% of the stock is owned by institutional investors.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.